General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Hoth Surges on Collaboration With Voltron for COVID-19 Vaccine | news.google.com • |
Hoth Therapeutics (HOTH) Up on Upbeat Alzheimer's Drug Data | zacks.com • |
Hoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024 | prnewswire.com • |
Why Is Hoth Therapeutics (HOTH) Stock Up 83% Today? | investorplace.com • |
Are Penny Stocks Worth the Risk? 3 Reasons Why They Could Be | pennystocks.com • |
Why Hoth Therapeutics Shares Are Nosediving - Hoth Therapeutics (NASDAQ:HOTH) | benzinga.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-20 | 2024-03 | -0.43 | N/A | N/A | N/A |
2024-03-29 | 2023-12 | -0.49 | N/A | N/A | N/A |
2023-11-13 | 2023-09 | 0 | -0.6 | N/A | N/A |
2023-11-13 | 2023-09 | 0 | N/A | N/A | N/A |
2023-08-11 | 2023-06 | 0 | -0.57 | N/A | N/A |
2023-08-11 | 2023-06 | 0 | N/A | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-13 | EF Hutton | Upgrade | Buy | Buy |
2023-06-19 | Benchmark | Upgrade | Speculative Buy | Speculative Buy |
2023-04-26 | EF Hutton | Upgrade | Buy | |
2023-04-09 | Benchmark | Upgrade | Speculative Buy | |
2023-04-02 | EF Hutton | Upgrade | Buy | |
2022-12-29 | EF Hutton | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2019-02-19 | EITNER MATTHEW D | Beneficial Owner of more than 10% of a Class of Security | 765.00K | Conversion of Exercise of derivative security |
2020-05-25 | HAYES ANTHONY | Beneficial Owner of more than 10% of a Class of Security | 1.13M | Sale |
2022-09-18 | KNIE ROBB | Chief Executive Officer | 828.26K | Purchase |
2020-04-14 | LINSLEY WAYNE | Director | 3.33K | Stock Award(Grant) |
2022-12-12 | PAVELL JEFF | Director | 5.08K | Stock Award(Grant) |
2019-02-19 | POOR KEVIN JESS | Beneficial Owner of more than 10% of a Class of Security | 750.00K | Conversion of Exercise of derivative security |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Geode Capital Management, LLC | 24.34K | 73.02K | 0.74% |
2023-06-29 | Citadel Advisors Llc | 20.43K | 61.28K | 0.62% |
2023-06-29 | Vanguard Group Inc | 12.23K | 36.70K | 0.37% |
2023-06-29 | Integrated Wealth Concepts LLC | 10.00K | 30.00K | 0.30% |
2023-06-29 | UBS Group AG | 4.29K | 12.88K | 0.13% |
2023-06-29 | Royal Bank of Canada | 240.00 | 720.00 | 0.01% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Extended Market Index Fund | 12.23K | 36.70K | 0.37% |
2023-05-30 | Fidelity Extended Market Index Fund | 2.59K | 4.12K | 0.08% |
2023-05-30 | Fidelity NASDAQ Composite Index Fund | 1.99K | 3.16K | 0.06% |
2023-05-30 | Fidelity Series Total Market Index Fund | 702.00 | 1.12K | 0.02% |
Split | Date |
---|---|
1 : 25 | 2022-10-26 |
Press Release: Hoth Therapeutics Announces $10 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Mentioned: HOTH
Hoth Therapeutics Announces $10 Million Private Placement Priced At-the-Market Under Nasdaq Rules
PR Newswire
NEW YORK, Dec. 29, 2022
NEW YORK, Dec. 29, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 2,000,000 shares of its common stock (or common stock equivalent in lieu thereof) and warrants to purchase up to an aggregate of 2,500,000 shares of common stock, at a purchase price of $5.00 per share and accompanying warrant in a private placement priced at-the-market under Nasdaq rules. The gross proceeds to the Company from the private placement are expected to be $10 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The private placement is expected to close on or about January 3, 2023, subject to the satisfaction of customary closing conditions.
Analyst Forecast
According to 8 analysts, the average rating for HOTH stock is "Buy." The 12-month stock price forecast is $25.5, which is an increase of 137.87% from the latest price.
Price Target
$25.5
(137.87% upside)
Analyst Consensus: Buy
StrongSell
Sell
Hold
Buy
Strong
Hoth Therapeutics Announces Partnership With Altasciences For Manufacturing HT-TBI For Traumatic Brain Injury And Stroke
Mentioned: HOTH
NEW YORK, Sept. 20, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, today announced it has signed an agreement with Altasciences, a fully integrated early phase CRO/CDMO, to develop and manufacture the HT-TBI drug product formulation. HT-TBI is being developed as a novel, point-of-care therapy for the treatment and/or prevention of secondary brain injury (e.g., brain edema and inflammation) resulting from ischemic stroke and traumatic brain injury ("TBI"). HT-TBI will be developed as a ready-to-use drug-device combination product for use in non-healthcare settings by patients and caregivers at risk for stroke/TBI, emergency healthcare professionals, and military personnel.
Have a look at $ALNA!! Uptrend But do your own research!!
Analyst Forecast
According to 8 analysts, the average rating for HOTH stock is "Buy." The 12-month stock price forecast is 3.06, which is an increase of 665.00% from the latest price.
Price Target
$3.06
(665.00% upside)
Analyst Consensus: Buy
Chart
Bar chart with 5 bars.
The chart has 1 X axis displaying categories.
The chart has 1 Y axis displaying values. Data ranges from 0 to 5.
$HOTH GETTING READY TO FLY AGAIN!!
$HOTH Consolidation will be ending today!!! It’s about time this baby SOARS AGAIN! Blessed to be in this stock! Do your DD people!
$HOTH today was nothing compared to the run that’s coming. Today was a hundred meter dash compared to the marathon that’s approaching!
$HOTH Love it when the paid bashers and shorts come out on the board!! They’re scared!
$HOTH MULTI-DAY, 1000% RUNNER!!
Analyst Forecast
According to 8 analysts, the average rating for HOTH stock is "Buy." The 12-month stock price forecast is 3.83, which is an increase of 187.97% from the latest price.
Price Target
$3.83
(187.97% upside)
Analyst Consensus: Buy